Recent Advances in MDS and CML

home / peer-exchange / mds-cml
Introduction: Treatment Landscape of MDS

EP. 1: Introduction: Treatment Landscape of MDS

January 9th 2014
Discontinuation of Treatment With TKIs in CML

EP. 2: Discontinuation of Treatment With TKIs in CML

January 9th 2014
Frontline Treatment of Chronic Myelogenous Leukemia

EP. 3: Frontline Treatment of Chronic Myelogenous Leukemia

January 9th 2014
Second-Generation Tyrosine Kinase Inhibitors in CML

EP. 4: Second-Generation Tyrosine Kinase Inhibitors in CML

January 9th 2014
Treatment Selection for Resistant or Intolerant CML

EP. 5: Treatment Selection for Resistant or Intolerant CML

January 9th 2014
Hypomethylating Agents in the Treatment of High-Risk MDS

EP. 6: Hypomethylating Agents in the Treatment of High-Risk MDS

January 9th 2014
Role of Genetic Testing in Myelodysplastic Syndromes

EP. 7: Role of Genetic Testing in Myelodysplastic Syndromes

January 9th 2014
Defining and Predicting Response to HMAs in MDS

EP. 8: Defining and Predicting Response to HMAs in MDS

January 9th 2014
Treatment of MDS Refractory to Hypomethylating Agent

EP. 9: Treatment of MDS Refractory to Hypomethylating Agent

January 9th 2014
Current and Future Treatment Landscape for MDS

EP. 10: Current and Future Treatment Landscape for MDS

January 9th 2014
Novel Agents and Treatment Strategies in MDS

EP. 11: Novel Agents and Treatment Strategies in MDS

January 9th 2014
Oral Azacitidine and Lenalidomide Combinations in MDS

EP. 12: Oral Azacitidine and Lenalidomide Combinations in MDS

January 9th 2014
Final Thoughts on Clinical Advances in MDS and CML

EP. 13: Final Thoughts on Clinical Advances in MDS and CML

January 9th 2014